Because of the elevated density of peptide-specific cytotoxic T lymphocytes (CTLs) in the TME, HCC patients with high GPC-3 expression in tumor tissues and/or high content of GPC-3 in plasma have a high response rate and a good prognosis for the GPC-3 vaccine [216]. This evidence concerns the gene GPC3 and hepatocellular carcinoma.